Form 4: Amicus Therapeutics Officer Sells Shares

Amicus Therapeutics' Chief People Officer, David Michael Clark, sold 25,643 shares of common stock for a weighted average price of $10.0976 per share.

Summary

• David Michael Clark, the Chief People Officer of Amicus Therapeutics, Inc. (FOLD), disposed of 25,643 shares of common stock.
• The transaction occurred on November 24, 2025, at a weighted average price of $10.0976 per share.
• The sale was executed pursuant to a Rule 10b5-1 trading plan, which was adopted by the reporting person on March 14, 2025.
• Following this transaction, David Michael Clark beneficially owns 296,975 shares of Amicus Therapeutics common stock.
• The prices for the transactions ranged from $10.00 to $10.32 per share.

Sentiment

Score: 5

Explanation: The filing reports a routine insider stock sale executed under a pre-arranged 10b5-1 trading plan, which is a common practice for executives and generally considered neutral in terms of company sentiment.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This is a routine insider transaction disclosure (Form 4) and does not provide specific insights into broader industry trends or competitive landscape. Such sales under a pre-arranged 10b5-1 plan are common for executives managing personal finances.

Stakeholder Impact

• Shareholders: A routine insider sale under a 10b5-1 plan typically has minimal direct impact on shareholder sentiment, as it is a pre-scheduled personal financial management event rather than a reflection of new company-specific news.

Key Dates

Keywords

Amicus Therapeutics, FOLD, Insider Trading, Form 4, Stock Sale, Chief People Officer, 10b5-1 Plan, Biotechnology, Pharmaceuticals